Integrase

Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities

Retrieved on: 
Wednesday, March 6, 2024
Biotechnology, AIDS, Hospitals, Health, Pharmaceutical, ARV, Week, Research, Doctor of Philosophy, CROI, Science, CAPRISA, TLD, Fever, Coinfection, TB, STR, Common, Health care, Organization, DTG, Drug resistance, Genotype, HBV, Fungal infection, Principal, Rifampicin, Seroconversion, Tablet, ALT, TDF, Conference, Safety, Biomarker, Pharmacokinetics, Integrase, Metabolism, Emtricitabine, Aes, Gilead Sciences, MD, FDA, Upper respiratory tract infection, Food, Cell, Risk, Prevalence, COVID-19, Death, Patient, HIV/AIDS, Tuberculosis, INSIGHT, HIV, Vaccine

“People with HIV and comorbid conditions or pre-existing treatment resistance can often face complex and evolving treatment needs.

Key Points: 
  • “People with HIV and comorbid conditions or pre-existing treatment resistance can often face complex and evolving treatment needs.
  • The ALLIANCE trial is the first randomized clinical trial of TAF- vs TDF-based regimens in treatment naïve adults with HIV /HBV coinfection.
  • Additionally, ALLIANCE participants treated with Biktarvy exhibited numerically higher levels of HBV viral suppression and seroconversion.
  • The primary outcome measure is viral suppression rates at Week 24, defined as HIV-1 RNA ˂50 copies/mL.

Thermo Fisher Scientific to Showcase New Innovative Laboratory Solutions at AMP 2022

Retrieved on: 
Monday, October 31, 2022
Manufacturing, Other Manufacturing, Science, Other Science, Research, PCR, Invitrogen, AMP, Somatic mutation, Urinary tract infection, Therapy, PPD, CGP, Thermo Fisher Scientific, NGS, Phoenix Convention Center, HRD, Research, Solution, Infection, GIM, Association, Vertically transmitted infection, HIV, Drug resistance, Program, Pharmaceutical Services Negotiating Committee, Integrase, IVD, Emergency Use Authorization, Genome, Patheon, OEM, Applied Biosystems, MAP, Liquid biopsy, Senior, Technology, Fisher Scientific, Degenerative disease, Polymerase, Digital, Mindful Scientific Inc., Genomics, Severe acute respiratory syndrome coronavirus 2, COVID-19, Workflow, CE, Health, Thermo, Face, Laboratory, Science, Medical imaging, Medical device, Vaccine, Pharmaceutical industry

Thermo Fisher Scientific, the world leader in serving science, is showcasing its latest innovative research and diagnostic technologies at the 2022 annual meeting and expo of the Association for Molecular Pathology (AMP) taking place at the Phoenix Convention Center from Nov. 1-5.

Key Points: 
  • Thermo Fisher Scientific, the world leader in serving science, is showcasing its latest innovative research and diagnostic technologies at the 2022 annual meeting and expo of the Association for Molecular Pathology (AMP) taking place at the Phoenix Convention Center from Nov. 1-5.
  • Thermo Fishers newly expanded Absolute Q Liquid Biopsy dPCR Assays * include products that enable reproducible, specific detection of known somatic mutations for cancer research.
  • Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion.
  • Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

Thermo Fisher Scientific Launches Enhanced Applied Biosystems HIV-1 Genotyping Kit

Retrieved on: 
Monday, August 8, 2022
Health, Infectious Diseases, Other Science, General Health, Research, Science, Biotechnology, Public health, Laboratory, Mindful Scientific Inc., Genetic testing, Population, Drug resistance, Patheon, Research, Fisher Scientific, Invitrogen, Plasma, Thermo Fisher Scientific, Pharmaceutical Services Negotiating Committee, Therapy, MagMax, PPD, 2017 Africa Cup of Nations qualification Group M, RNA, Integrase, EDTA, Applied Biosystems, Science, HIV, UNAIDS, Health, Vaccine

Thermo Fisher Scientific, the world leader in serving science, today announced the launch of its Applied Biosystems HIV-1 Genotyping Kit with Integrase, a research use only assay that examines positive samples of human immunodeficiency virus (HIV) to identify genetic variants that resist common antiretrovial therapeutics.

Key Points: 
  • Thermo Fisher Scientific, the world leader in serving science, today announced the launch of its Applied Biosystems HIV-1 Genotyping Kit with Integrase, a research use only assay that examines positive samples of human immunodeficiency virus (HIV) to identify genetic variants that resist common antiretrovial therapeutics.
  • The Applied Biosystems HIV-1 Genotyping Kit will analyze expanded targets associated with HIV drug resistance that include mutations in the integrase region of the pol gene on Applied Biosystems Sanger sequencing CE instrumentation.
  • Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion.
  • Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

Serotiny and Tessera Therapeutics enter into collaboration to engineer and optimize programmable Gene Writer proteins

Retrieved on: 
Monday, February 28, 2022
Other Health, Research, General Health, Professional Services, Pharmaceutical, Venture Capital, Medical Devices, Genetics, Science, Biotechnology, Other Science, Health, Geoffrey von Maltzahn, Health, Mobile genetic elements, Gene, Chimeric antigen receptor T cell, Efficiency, RNA, Protein, Reverse transcriptase, RNA transfection, TMDP, CAR, Therapy, Genome, Flagship Pioneering, Heart, Canadian Aviation Regulations, Machine learning, DNA, MGE, Biotechnology, Recombinase, Integrase, Engineering, Technology, Synthetic biology, Patient, Mining, CEO, Research, Doctor of Philosophy, Vaccine, Antibiotics, Serotiny, Tessera, Serotiny, Tessera’s Gene Writer platform, Tessera Therapeutics, SEROTINY, TESSERA’S GENE WRITER PLATFORM, TESSERA THERAPEUTICS

Serotiny, a leader in high-throughput therapeutic Multi-Domain Protein (tMDP) engineering, and Tessera Therapeutics, a biotechnology company pioneering a new approach in genetic medicines known as Gene Writing technology, today announced a collaboration to engineer programmable Gene Writer proteins.

Key Points: 
  • Serotiny, a leader in high-throughput therapeutic Multi-Domain Protein (tMDP) engineering, and Tessera Therapeutics, a biotechnology company pioneering a new approach in genetic medicines known as Gene Writing technology, today announced a collaboration to engineer programmable Gene Writer proteins.
  • This collaboration will build on Tesseras innovations in genome engineering technologies and apply Serotinys tMDP mining and design expertise to further optimize Tesseras programmable Gene Writer proteins, capable of making diverse and directed alterations to the genome.
  • By partnering with Serotiny, Tessera will have the ability to identify, screen, and optimize a variety of proteins that can serve as the foundation of future Gene Writer therapies across a variety of disease states.
  • Serotinys multi-domain engineering expertise has the potential to further optimize our Gene Writer protein libraries and were delighted to partner with the Serotiny team.

Healthcare providers can expect to receive US$725 reimbursement from CMS when using NGS-based Sentosa(R) SQ HIV-1 Genotyping Assay

Retrieved on: 
Friday, January 7, 2022
Immunodeficiency, COVID-19, Severe acute respiratory syndrome coronavirus 2, CMS, DNA sequencing, Omicron, Patient, PCR, Centers for Medicare & Medicaid Services, Laboratory, IVD, NGS, Automation, HIV, Drug resistance, Efficiency, CEO, CPT, Infection, FDA, Integrase, Genome, Method, Board, Center, Technology, VELA, Solution, Stanford University, Medicare, Singapore, Medical device, Pharmaceutical industry, Sentosa, Medicaid

Based on the 2022 Clinical Diagnostic Laboratory Fee Schedule by CMS, healthcare providers using the Sentosa SQ HIV-1 Genotyping Assay solution with the assigned descriptor for therapeutic diagnoses can expect a reimbursement of US$725 using CPT code 0219U for HIV gene analysis*.

Key Points: 
  • Based on the 2022 Clinical Diagnostic Laboratory Fee Schedule by CMS, healthcare providers using the Sentosa SQ HIV-1 Genotyping Assay solution with the assigned descriptor for therapeutic diagnoses can expect a reimbursement of US$725 using CPT code 0219U for HIV gene analysis*.
  • The assay analyses three key drug targets (Protease, Reverse Transcriptase and Integrase) within a virus's genome, in a single run.
  • Analysis of the Integrase gene is notable this Sentosa assay is currently the only FDA-authorized genotyping assay with this capability.
  • "We are the encouraged that CMS now reimburses our Sentosa SQ HIV-1 Genotyping Assay.

Healthcare providers can expect to receive US$725 reimbursement from CMS when using NGS-based Sentosa(R) SQ HIV-1 Genotyping Assay

Retrieved on: 
Friday, January 7, 2022
Immunodeficiency, COVID-19, Severe acute respiratory syndrome coronavirus 2, CMS, DNA sequencing, Omicron, Patient, PCR, Centers for Medicare & Medicaid Services, Laboratory, IVD, NGS, Automation, HIV, Drug resistance, Efficiency, CEO, CPT, Infection, FDA, Integrase, Genome, Method, Board, Center, Technology, VELA, Solution, Stanford University, Medicare, Singapore, Medical device, Pharmaceutical industry, Sentosa, Medicaid

Based on the 2022 Clinical Diagnostic Laboratory Fee Schedule by CMS, healthcare providers using the Sentosa SQ HIV-1 Genotyping Assay solution with the assigned descriptor for therapeutic diagnoses can expect a reimbursement of US$725 using CPT code 0219U for HIV gene analysis*.

Key Points: 
  • Based on the 2022 Clinical Diagnostic Laboratory Fee Schedule by CMS, healthcare providers using the Sentosa SQ HIV-1 Genotyping Assay solution with the assigned descriptor for therapeutic diagnoses can expect a reimbursement of US$725 using CPT code 0219U for HIV gene analysis*.
  • The assay analyses three key drug targets (Protease, Reverse Transcriptase and Integrase) within a virus's genome, in a single run.
  • Analysis of the Integrase gene is notable this Sentosa assay is currently the only FDA-authorized genotyping assay with this capability.
  • "We are the encouraged that CMS now reimburses our Sentosa SQ HIV-1 Genotyping Assay.

Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV

Retrieved on: 
Monday, March 15, 2021
Biotechnology, Hospitals, Health, Pharmaceutical, Clinical trials, Integrase inhibitors, Life sciences, Biotechnology, Gilead Sciences, Drugs, Islatravir, Integrase, BI 224436, Merck & Co., Islatravir (MK-8591), Lenacapavir, Gilead Sciences, Merck

Through this agreement with Merck, Gilead is reinforcing its long-term role in transforming HIV care, said Daniel ODay, Chairman and Chief Executive Officer, Gilead Sciences.

Key Points: 
  • Through this agreement with Merck, Gilead is reinforcing its long-term role in transforming HIV care, said Daniel ODay, Chairman and Chief Executive Officer, Gilead Sciences.
  • Lenacapavir and islatravir, alone and in combination, are investigational and not approved anywhere globally.
  • Beyond the potential combinations of lenacapavir and islatravir, Gilead will have the option to license certain of Mercks investigational oral integrase inhibitors to develop in combination with lenacapavir.
  • Reciprocally, Merck will have the option to license certain of Gileads investigational oral integrase inhibitors to develop in combination with islatravir.